Portfolio — seedfolio

ACQUIRED. Improving lower pelvic surgeries with faster safer ureter identification

AmplifiDx: Faster and 10x cheaper than PCR. The next point-of-care molecular diagnostics platform.

Amplo is treating diseases of the neuro-muscular junction (including congenital myasthenia syndrome, ALS, and muscular dystrophies) by one-time Dok7-gene therapy

Anvil uses existing ultrasensitive dPCR, but tricks it out to turn 6 channels into 63 for specific-pathogen identification. Sepsis path ID in 2 hours at POC instead of 2 days by culture.

Basilard has a novel mechanoporation device for non-viral ex-vivo transfection with greater efficiency and cell viability than electroporation.

Califia Pharma: The inventor of irofulven has developed a better/safer version and precision-medicine approach to treat multiple cancer types

Chronus is developing the first point-of-care device to measure both CBC and CMP in minutes at high accuracy and low cost. CBC and CMP account for 50% of all lab tests and $9b of market size.

Delpor’s platform delivers drugs at stable levels for up to 12 months from a single implant.

Duo Oncology has novel polymeric micelles small enough (15nm) to penetrate stroma in tumors (like pancreatic) and deliver proven payloads.

Earthgrid has “groundbreaking” tunnel-boring technology to allow renewable projects to more easily connect to the grid.

eGlint has a novel detection approach to leverage aptamers for fast, low-cost, high-accuracy, high-multiplex diagnostics

Ekefalos is developing cyclotides to deliver proteins (enzymes, antibodies, growth factors) across the blood brain barrier

Portable solar/battery towers for lights/comms/security, with no tow-hitch needed. Elegant design. Compact package. Industrial ruggedness. For construction, military/first-responders, sports, and events.

Hap10 is developing antibodies targeting haptens of inhibited KRAS12C. From the UCSF Labs of Charles Craik and Kevan Shokat.

Himalaya Therapeutics has xclusive access in China to BioAtla’s “CAB” therapeutics to treat cancer

Interface Bioscience uses AI and secret sauce to map the full metabolome of the human microbiome (skin and gut) and use this novel library and data to find novel immunomodulating agents. They are starting with eczema and then IBD.

InProther has a novel cancer vaccine targeting human endogenous retrovirus

Ivy Energy provides an “Easy Button” for landlords to leverage VNEM to profitably add solar to their apartments.

Kinathera is developing a novel oral inhibitor of type 1 interferon to treat auto-immune diseases.

Leap has a revolutionary process to manufacture solar cells without wafers

Life Detection Technologies prevents hospitalization by predicting COPD exacerbations through non-contact overnight monitoring of heart and respiration rates.

Lilium has achieved the trifecta of in-vivo gene delivery (cell-specific targeting, no liver sink, no immunogenicity)

Maxwell Biomedical is developing an electronic implantable device to correct atrial fibrillation

Myogenica is advancing progenitor muscle stem cells to treat muscular dystrophies.

NanoPharma Solutions increases the solubility of drugs without solvents or stabilizers. Great for intranasal and inhalable formulations.

Novel Biotechnology manufactures DNA plasmids using a proprietary bacterial strain. A drop-in replacement for e. coli, it can produce challenging plasmids at higher yield in less time.

Ordaos has a best-in-class team and AI system to generate mini proteins. Compared to typical antibody screening, they deliver leads with 1000x more affinity in 1/10th the time.

Particella has novel lipid nanoparticles for ORAL delivery of mRNA to the intestine

Palm Therapeutics has developed a novel, rapid screening system to find protein-specific inhibitors of palmitoylation. First target is pan-NRAS-mutant cancers.

PercAssist is developing the first minimally invasive heart-assist device

Preview Medical is improving the diagnosis and treatment of prostate cancer

Progentos is developing a small molecule to reverse the course of multiple sclerosis.

Pulmair is developing stents for lungs to keep airways open

Pyrojas is developing personalized, durable, effective cancer vaccines—with a twist. They isolate a patient’s cancer cells, genetically and chemically modify them, and reinject them into the patient.

RecoverX has AI (without hallucinations) for differntial diagnosis at point of care, based on ground truth like JAMA and BMJ, helping clinicians make better faster diagnoses

Regenosine delivers natural adenosine to regrow cartilage to reverse arthritis.

Remedium has developed a novel gene therapy delivery platform. They load DNA into proprietary LNPs, inject those subcutaneously, and turn fat cells into protein factories. For just one example: a single injection to produce stable GLP1 for 3+ years. Unique among gene therapies, they can later adjust the dose up or DOWN.

Resynergi is converting waste plastic into diesel or naptha (raw material for plastic) by microwave pyrolysis

Ruby has Robotics and AI to autonomously prepare, image and assess tissue during biopsy procedures

S2 Genomics is developing a device to process solid tissues into single-cells or nuclei for sequencing

Sirpant quickly modifyies a patient’s own macrophages to elicit a broad-spectrum immune response to fight cancer locally and vaccinate systemically

Tiamat is using plants to produce mammalian proteins at low cost and high scale for cultured meats and biotech

Trio Pharmaceuticals is developing novel quadrivalent bi-specifics to fight cancer

Vasa Therapeutics is developing multiple novel therapies for vascular disease and heart failure

Veckta is building the leading global marketplace for design, optimization, and procurement of onsite energy systems

VerImmune is redirecting previously acquired viral immunity to fight cancer

Xeno Biosciences is tackling the massive obesity epidemic with a revolutionary pill.

seedfolio investments and their mpact

FUND 2 INVESTMENTS

FUND 1b INVESTMENTS

FUND 1a INVESTMENTS